• Je něco špatně v tomto záznamu ?

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis

RČ. Pařízková, J. Martínková, E. Havel, P. Šafránek, M. Kaška, D. Astapenko, J. Bezouška, J. Chládek, V. Černý

. 2021 ; 25 (1) : 251. [pub] 20210717

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004079

Grantová podpora
PROGRES Q40/04 Ministerstvo Školství, Mládeže a Tělovýchovy
NT14089-3/2013 Ministerstvo Zdravotnictví Ceské Republiky
15-31881A Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Meropenem dosing for septic critically patients is difficult due to pathophysiological changes associated with sepsis as well as supportive symptomatic therapies. A prospective single-center study assessed whether fluid retention alters meropenem pharmacokinetics and the achievement of the pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy. METHODS: Twenty-five septic ICU patients (19 m, 6f) aged 32-86 years with the mean APACHE II score of 20.2 (range 11-33), suffering mainly from perioperative intra-abdominal or respiratory infections and septic shock (n = 18), were investigated over three days after the start of extended 3-h i.v. infusions of meropenem q8h. Urinary creatinine clearance (CLcr) and cumulative fluid balance (CFB) were measured daily. Plasma meropenem was measured, and Bayesian estimates of PK parameters were calculated. RESULTS: Eleven patients (9 with peritonitis) were classified as fluid overload (FO) based on a positive day 1 CFB of more than 10% body weight. Compared to NoFO patients (n = 14, 11 with pneumonia), the FO patients had a lower meropenem clearance (CLme 8.5 ± 3.2 vs 11.5 ± 3.5 L/h), higher volume of distribution (V1 14.9 ± 3.5 vs 13.5 ± 4.1 L) and longer half-life (t1/2 1.4 ± 0.63 vs 0.92 ± 0.54 h) (p < 0.05). Over three days, the CFB of the FO patients decreased (11.7 ± 3.3 vs 6.7 ± 4.3 L, p < 0.05) and the PK parameters reached the values comparable with NoFO patients (CLme 12.4 ± 3.8 vs 11.5 ± 2.0 L/h, V1 13.7 ± 2.0 vs 14.0 ± 5.1 L, t1/2 0.81 ± 0.23 vs 0.87 ± 0.40 h). The CLcr and Cockroft-Gault CLcr were stable in time and comparable. The correlation with CLme was weak to moderate (CLcr, day 3 CGCLcr) or absent (day 1 and 2 CGCLcr). Dosing with 2 g meropenem q8h ensured adequate concentrations to treat infections with sensitive pathogens (MIC 2 mg/L). The proportion of pre-dose concentrations exceeding the MIC 8 mg/L and the fraction time with a target-exceeding concentration were higher in the FO group (day 1-3 f Cmin > MIC: 67 vs 27%, p < 0.001; day 1%f T > MIC: 79 ± 17 vs 58 ± 17, p < 0.05). CONCLUSIONS: These findings emphasize the importance of TDM and a cautious approach to augmented maintenance dosing of meropenem to patients with FO infected with less susceptible pathogens, if guided by population covariate relationships between CLme and creatinine clearance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004079
003      
CZ-PrNML
005      
20220127145600.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13054-021-03680-9 $2 doi
035    __
$a (PubMed)34274013
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pařízková, Renata Černá $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
245    10
$a Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis / $c RČ. Pařízková, J. Martínková, E. Havel, P. Šafránek, M. Kaška, D. Astapenko, J. Bezouška, J. Chládek, V. Černý
520    9_
$a BACKGROUND: Meropenem dosing for septic critically patients is difficult due to pathophysiological changes associated with sepsis as well as supportive symptomatic therapies. A prospective single-center study assessed whether fluid retention alters meropenem pharmacokinetics and the achievement of the pharmacokinetic/pharmacodynamic (PK/PD) targets for efficacy. METHODS: Twenty-five septic ICU patients (19 m, 6f) aged 32-86 years with the mean APACHE II score of 20.2 (range 11-33), suffering mainly from perioperative intra-abdominal or respiratory infections and septic shock (n = 18), were investigated over three days after the start of extended 3-h i.v. infusions of meropenem q8h. Urinary creatinine clearance (CLcr) and cumulative fluid balance (CFB) were measured daily. Plasma meropenem was measured, and Bayesian estimates of PK parameters were calculated. RESULTS: Eleven patients (9 with peritonitis) were classified as fluid overload (FO) based on a positive day 1 CFB of more than 10% body weight. Compared to NoFO patients (n = 14, 11 with pneumonia), the FO patients had a lower meropenem clearance (CLme 8.5 ± 3.2 vs 11.5 ± 3.5 L/h), higher volume of distribution (V1 14.9 ± 3.5 vs 13.5 ± 4.1 L) and longer half-life (t1/2 1.4 ± 0.63 vs 0.92 ± 0.54 h) (p < 0.05). Over three days, the CFB of the FO patients decreased (11.7 ± 3.3 vs 6.7 ± 4.3 L, p < 0.05) and the PK parameters reached the values comparable with NoFO patients (CLme 12.4 ± 3.8 vs 11.5 ± 2.0 L/h, V1 13.7 ± 2.0 vs 14.0 ± 5.1 L, t1/2 0.81 ± 0.23 vs 0.87 ± 0.40 h). The CLcr and Cockroft-Gault CLcr were stable in time and comparable. The correlation with CLme was weak to moderate (CLcr, day 3 CGCLcr) or absent (day 1 and 2 CGCLcr). Dosing with 2 g meropenem q8h ensured adequate concentrations to treat infections with sensitive pathogens (MIC 2 mg/L). The proportion of pre-dose concentrations exceeding the MIC 8 mg/L and the fraction time with a target-exceeding concentration were higher in the FO group (day 1-3 f Cmin > MIC: 67 vs 27%, p < 0.001; day 1%f T > MIC: 79 ± 17 vs 58 ± 17, p < 0.05). CONCLUSIONS: These findings emphasize the importance of TDM and a cautious approach to augmented maintenance dosing of meropenem to patients with FO infected with less susceptible pathogens, if guided by population covariate relationships between CLme and creatinine clearance.
650    _2
$a APACHE $7 D018806
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antibakteriální látky $x metabolismus $x farmakokinetika $7 D000900
650    _2
$a Bayesova věta $7 D001499
650    _2
$a kritický stav $x terapie $7 D016638
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a jednotky intenzivní péče $x organizace a řízení $x statistika a číselné údaje $7 D007362
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meropenem $x metabolismus $x farmakokinetika $7 D000077731
650    _2
$a lidé středního věku $7 D008875
650    12
$a farmakokinetika $7 D010599
650    _2
$a prospektivní studie $7 D011446
650    _2
$a sepse $x farmakoterapie $x patofyziologie $7 D018805
650    _2
$a vodní a elektrolytová rovnováha $x účinky léků $7 D014882
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Martínková, Jiřina $u Department of Surgery, University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Havel, Eduard $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Šafránek, Petr $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Kaška, Milan $u Department of Surgery, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Astapenko, David $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Bezouška, Jan $u Department of Surgery, University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
700    1_
$a Chládek, Jaroslav $u Department of Pharmacology, Charles University, Faculty of Medicine in Hradec Králové, Šimkova 870, 50003, Hradec Králové, Czech Republic. chladekj@lfhk.cuni.cz
700    1_
$a Černý, Vladimír $u Department of Anesthesiology, Resuscitation and Intensive Medicine, Charles University, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Sokolská 581, 50005, Hradec Králové, Czech Republic
773    0_
$w MED00006603 $t Critical care (London, England) $x 1466-609X $g Roč. 25, č. 1 (2021), s. 251
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34274013 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145556 $b ABA008
999    __
$a ok $b bmc $g 1751515 $s 1155228
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 25 $c 1 $d 251 $e 20210717 $i 1466-609X $m Critical care $n Crit Care $x MED00006603
GRA    __
$a PROGRES Q40/04 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a NT14089-3/2013 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a 15-31881A $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...